Companies › Tangram Therapeutics
2 active drug programs in 2 registered trials: 2 Phase 1; Metabolic and endocrine, Other; next expected readout Mar 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TGM-148 | – | Phase 1 | Healthy Participants | Mar 2028 |
| TGM-312-SC01 | – | Phase 1 | Healthy Participants | Mar 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07427680 | TGM-312-SC01 | Phase 1 | Healthy Participants | Metabolic and endocrine | Mar 2028 |
| NCT07843368 | TGM-148 | Phase 1 | Healthy Participants | Other | Mar 2028 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.